Skip to main content
Premium Trial:

Request an Annual Quote

Cellectis Bioresearch Inks Canadian Distribution Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis Bioresearch, a subsidiary of French firm Cellectis, said Tuesday that Cedarlane will distribute Cellectis Bioresearch's kits in Canada.

Cellectis said that it will be responsible for the design and production of targeted integration kits from its Cellular Genome Positioning System (cGPS) and cGPS Custom lines. Cedarlane will distribute the kits to research labs in Canada, providing Cellectis Bioresearch with a "foothold in the North American research market," the French firm said.

"Targeted integration using meganucleases – the basis of Cellectis bioresearch's kits – makes the generation of stable cell lines fast and effortless," Luc Selig, VP of sales and marketing for Cellectis Bioresearch, said in a statement. "This agreement will help us to rapidly expand the network of users for our kits."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.